Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19

30
8
Favorite

Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19

Dow Jones2021-09-01

Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. ""As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease," said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. "If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities." Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（8）

FALCON
·2021-09-01
Nice
Reply
1
Report
miyakos
·2021-09-01
Yes
Reply
1
Report
jj266
·2021-09-01
Ok
Reply
2
Report
Fold Replies
- miyakos:
  uk
  2021-09-01
  Reply
  Report
TATAN
·2021-09-01
Pls like
Reply
5
Report
Fold Replies
- ShanGe:
  ok
  2021-09-01
  Reply
  Report
- Raymond杨:
  ok
  2021-09-01
  Reply
  Report
KailashN
·2021-09-01
Good! Like please
Reply
5
Report
Fold Replies
- jj266:
  ok
  2021-09-01
  Reply
  Report
Gabrielle_20
·2021-09-01
???
Reply
5
Report
Yonakazuk
·2021-09-01
Another vaccine?!
Reply
4
Report
Jfierydragon
·2021-09-01
Like n coment
Reply
5
Report
Fold Replies
- Yonakazuk:
  Okay!
  2021-09-01
  Reply
  Report
- Qarah:
  Like and comment back thanks!
  2021-09-01
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2164894947?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-01 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2164894947","market":"us","top_or_hot":-1,"title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","media":"Dow Jones","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n2021-09-01 18:58 北京时间&nbsp;&nbsp;&nbsp;<strong>Dow Jones</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRK","symbol_name":"默沙东","start_time":0,"source_url":null,"article_id":"2164894947","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","pubTimestamp":1630493880,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRK":"默沙东","XLV":"健康照护类股ETF-SPDR"},"translate_title":"默沙东，Ridgeback开始口服药物预防新冠肺炎的3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9,"XLV":0.9},"content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":816683950,"gmtCreate":1630496055670,"gmtModify":1676530319791,"author":{"id":"3584817540991212","authorId":"3584817540991212","name":"FALCON","avatar":"https://static.tigerbbs.com/c0d98873fea539ae720f8695900f4238","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816683950","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":816689882,"gmtCreate":1630495932646,"gmtModify":1676530319783,"author":{"id":"4088416347172780","authorId":"4088416347172780","name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816689882","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":816612846,"gmtCreate":1630495565785,"gmtModify":1676530319503,"author":{"id":"3582868043238924","authorId":"3582868043238924","name":"jj266","avatar":"https://static.tigerbbs.com/7f964e4d85d7cb1a9afa6f4b6fea411c","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/816612846","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5717851,"gmtCreate":1630495946343,"gmtModify":1663233228236,"authorId":4088416347172780,"author":{"id":4088416347172780,"authorId":4088416347172780,"name":"miyakos","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816612846,"type":1,"supId":0,"prevId":0,"content":"uk","text":"uk","html":"uk"}],"langContent":"EN"},{"id":816637851,"gmtCreate":1630494888873,"gmtModify":1676530319363,"author":{"id":"4088469874187460","authorId":"4088469874187460","name":"TATAN","avatar":"https://static.tigerbbs.com/5bbf7eea3fe8e8e487b5997dfdf4aa15","vip":1,"crmLevel":5,"crmLevelSwitch":1},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/816637851","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5717762,"gmtCreate":1630495180627,"gmtModify":1663233225730,"authorId":3582538893691109,"author":{"id":3582538893691109,"authorId":3582538893691109,"name":"ShanGe","avatar":"https://static.tigerbbs.com/d4a011d6f4f4fea0a80bcb10d98906e0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816637851,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":5717736,"gmtCreate":1630494979105,"gmtModify":1663233225443,"authorId":3560481430779928,"author":{"id":3560481430779928,"authorId":3560481430779928,"name":"Raymond杨","avatar":"https://static.tigerbbs.com/a0e904d9a1021ec74841e99e765cf608","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816637851,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":816632599,"gmtCreate":1630494532911,"gmtModify":1676530319277,"author":{"id":"3582703680193232","authorId":"3582703680193232","name":"KailashN","avatar":"https://static.tigerbbs.com/bcea4d0815f5091810e222c8e9e54c35","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good! Like please","listText":"Good! Like please","text":"Good! Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/816632599","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5717805,"gmtCreate":1630495560635,"gmtModify":1663233227053,"authorId":3582868043238924,"author":{"id":3582868043238924,"authorId":3582868043238924,"name":"jj266","avatar":"https://static.tigerbbs.com/7f964e4d85d7cb1a9afa6f4b6fea411c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816632599,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":816636257,"gmtCreate":1630494375579,"gmtModify":1676530319262,"author":{"id":"3569531614182731","authorId":"3569531614182731","name":"Gabrielle_20","avatar":"https://static.tigerbbs.com/3687c03e4fcd937f9b3fa40fa7705b14","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816636257","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":816636172,"gmtCreate":1630494348196,"gmtModify":1676530319246,"author":{"id":"3582348929679840","authorId":"3582348929679840","name":"Yonakazuk","avatar":"https://static.tigerbbs.com/2692aaa50828068617038f2be6a6b9de","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":0},"htmlText":"Another vaccine?!&nbsp;","listText":"Another vaccine?!&nbsp;","text":"Another vaccine?!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816636172","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":816636349,"gmtCreate":1630494347581,"gmtModify":1676530319254,"author":{"id":"3579028995240368","authorId":"3579028995240368","name":"Jfierydragon","avatar":"https://static.tigerbbs.com/32ea74904661b2d0a43f0cc648caae68","vip":1,"crmLevel":9,"crmLevelSwitch":1},"htmlText":"Like n coment","listText":"Like n coment","text":"Like n coment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/816636349","repostId":2164894947,"repostType":4,"repost":{"id":"2164894947","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1630493880,"share":"https://www.laohu8.com/m/news/2164894947?lang=&edition=full","pubTime":"2021-09-01 18:58","market":"us","language":"en","title":"Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2164894947","media":"Dow Jones","summary":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have start","content":"<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Ridgeback start Phase 3 trial of oral drug to prevent COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-01 18:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Merck &amp; Co. Inc. <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164894947","content_text":"Shares of Merck & Co. Inc. $(MRK)$ and Ridgeback Biotherapeutics said Wednesday that they have started a Phase 3 trial of molnupiravir, and oral antiviral therapeutics for the prevention of COVID-19 infection. Merck's stock gained 0.4% in premarket trading. The drug makers said the study is enrolling people at least 18 years old who live in the same house as someone who tested positive for SARS-CoV-2 and had symptoms. Primary endpoints include percentage of participants with COVID-19 through day 14, the percentage of those with an adverse event and the percentage of those who had to discontinue to the study because of an adverse event. \"\"As the pandemic continues to evolve and surges are being reported in many places around the world, it is important that we investigate new ways to protect individuals exposed to the virus from becoming infected with symptomatic disease,\" said Dr. Nick Kartsonis, senior vice president, vaccines and infectious diseases, clinical research, Merck Research Laboratories. \"If successful, molnupiravir could provide an important additional option towards reducing the burden of COVID-19 on our communities.\" Merck's stock has slipped 2.2% year to date through Tuesday, while the SPDR Health Care Select Sector ETF $(XLV)$ has rallied 19.2% and the Dow Jones Industrial Average has advanced 15.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5717643,"gmtCreate":1630494357359,"gmtModify":1663233226630,"authorId":3582348929679840,"author":{"id":3582348929679840,"authorId":3582348929679840,"name":"Yonakazuk","avatar":"https://static.tigerbbs.com/2692aaa50828068617038f2be6a6b9de","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.19","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816636349,"type":1,"supId":0,"prevId":0,"content":"Okay!","text":"Okay!","html":"Okay!"},{"id":5717707,"gmtCreate":1630494805973,"gmtModify":1663233225541,"authorId":3570439473038184,"author":{"id":3570439473038184,"authorId":3570439473038184,"name":"Qarah","avatar":"https://static.tigerbbs.com/48285a44928a897dd5f255c626d5e9e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":816636349,"type":1,"supId":0,"prevId":0,"content":"Like and comment back thanks!","text":"Like and comment back thanks!","html":"Like and comment back thanks!"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":30,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}